AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1. (previously presented) A pharmaceutical composition for the treatment of hypoptyalism, comprising pilocarpine combined with at least one bioadhesive polymer so as to allow dissolution and local attachment to the tissues of the buccopharyngeal cavity.

2. (previously presented) The pharmaceutical composition according to claim 1, wherein the pilocarpine is the basic pilocarpine or pilocarpine in the form of salt, chlorohydrate or nitrate.

3. (previously presented) The pharmaceutical composition according to claim 1, wherein the composition is further combined with a mass substrate of the family of soluble carbohydrates with a low molecular weight, glucose or lactose.

4. (previously presented) The pharmaceutical composition according to claim 1, further comprising a buffer.

5. (previously presented) The pharmaceutical composition to claim 1, further comprising at least one lubricant.

6. (previously presented) The pharmaceutical composition according to claim 1, further comprising at least one softening agent.

7. (previously presented) The pharmaceutical composition according to claim 1, further comprising at least one hydrophilic substance.

8. (previously presented) A galenical formulation comprising the composition according to claim 1, wherein the formulation:

makes it possible for the pilocarpine to directly and instantaneously access the muscarine-like receptors of the submucous glandular structures;

protects the pilocarpine to keep it stable with regard to light, temperature and oxidation; and

allows the pilocarpine to dissolve and to attach locally to tissues of the buccopharyngeal cavity.

9. (previously presented) A sublingual tablet for the treatment of hypoptyalism, comprising the pharmaceutical composition according to claim 1.

10. (previously presented) The sublingual tablet according to claim 9, wherein the bioadhesive polymer is selected from the group consisting of: cellulose derivatives, gums or polymers of the alginic acid type and derivatives, carboxy-vinyl polymer, carbomer, macrogols, gelatin, povidone, and pectins.

11. (currently amended) The sublingual tablet according to claim 9, wherein the tablet comprises:

2.5 mg pilocarpine that is basic or in salt form,

10.0 mg magnesium stearate,

90.0 mg sodium or disodium hydrogen phosphate,

50.0 mg K 100 methocel,

40.0 mg polyethylene glycol, 6000

20.0 mg hyaluronic acid,

15.0 mg lysozyme ~~chlorohydrate~~, and

772.5 mg compressed sorbitol qsp for 1000 mg.

12. (previously presented) The sublingual tablet according to claim 11, wherein the sodium or disodium hydrogen phosphate is replaced by sodium carbonate or sodium bicarbonate in the same proportions.

13. (previously presented) The pharmaceutical composition according to claim 2, further comprising a buffer.

14. (previously presented) The pharmaceutical composition according to claim 3, further comprising a buffer.

15. (previously presented) The pharmaceutical according to claim 2, further comprising at least one lubricant.

16. (previously presented) The pharmaceutical composition according to claim 3, further comprising at least one lubricant.

17. (previously presented) The pharmaceutical composition according to claim 2, further comprising at least one softening agent.

18. (previously presented) The pharmaceutical composition according to claim 3, further comprising at least one softening agent.

19. (previously presented) The pharmaceutical composition according to claim 2, further comprising at least one hydrophilic substance.

20. (currently amended) The sublingual tablet according to claim 10, wherein the tablet comprises:

2.5 mg pilocarpine that is basic or in salt form,

10.0 mg magnesium stearate,

90.0 mg sodium or disodium hydrogen phosphate,

50.0 mg K 100 methocel,

40.0 mg polyethylene glycol 6000,

20.0 mg hyaluronic acid,

15.0 mg lysozyme ~~chlorohydrate~~, and

772.5 mg compressed sorbitol qsp for 1000 mg.